Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза IV Россия

Recombinant Protein-Free Factor VIII (rAHF-PFM); Recombinant Protein-Free Factor VIII (rAHF-PFM)

Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF PFM): A Phase 3/4, Prospective, Controlled, Randomized, Multi-Center Study to Compare the Efficacy and Safety of Continuous Infusion (CI) Versus Intermittent Bolus Infusion (BI) in Subjects With Severe or Moderately Severe Hemophilia A Undergoing Major Orthopedic Surgery

Номер протокола060402
ФазаФаза IV
Участников по плану — во всех странах исследования85
Сроки29.05.2006 — 09.12.2015
Начало: 29 мая 2006Окончание: 9 декабря 2015
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00357656/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: 18–70 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 85 чел. во всех странах исследования.
  • Центров в реестре: 3 в 3 городах. Список — ниже на странице.
  • Плановая дата окончания (12.2015) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст18–70 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 8 · невключение: 12

Критерии включения

  • The subject or the subject's legally authorized representative has provided signed informed consent.
  • The subject is within 18 to 70 years of age.
  • The subject has severe or moderately severe hemophilia A, defined by a baseline factor VIII level <= 2% of normal, as tested at screening. A subset of 15 subjects per group must have baseline factor VIII levels < 1% of normal.
  • The aPTT must be within the range of normal after administration of FVIII concentrate, as determined in the preoperative pharmacokinetic evaluation, or as documented in the medical history, if available.
  • The subject is scheduled to undergo an elective unilateral major orthopedic surgery that requires drain placement.
  • The subject was previously treated with factor VIII concentrate(s) for a minimum of at least 150 exposure days (as estimated by the investigator) prior to study entry.
  • Human immunodeficiency virus (HIV) positive subjects must be immunocompetent as determined with a CD4 count >= 200 cells/mm³ (CD4 count at screening), but HIV negative subjects with a CD4 count < 200 cells/mm³ qualify, if immunocompetency is documented.
  • The subject has a life expectancy of at least 28 days from the day of surgery.

Критерии невключения

  • The subject has a detectable factor VIII inhibitor at screening, with a titer >= 0.4 BU (Nijmegen modification of the Bethesda assay) in the central laboratory.
  • The subject has a history of factor VIII inhibitors with a titer >= 0.4 BU (by Nijmegen assay) or >= 0.5 BU (by Bethesda assay) at any time prior to screening.
  • The subject is scheduled to undergo any other concurrent minor or major surgery during the course of the study. The placement of central venous lines and the performance of fine needle aspiration biopsies are permitted.
  • Excluding hemophilia-related physical impairments, the subject is assigned to NYHA class >= III according to the New York Heart Association (NYHA).
  • The subject has an abnormal renal function (serum creatinine > 1.5 mg/dL).
  • The subject has active hepatic disease (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] levels > 5 times the upper limit of normal).
  • The subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) > 1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.
  • The subject has clinical and/or laboratory evidence of abnormal hemostasis from causes other than hemophilia A (e.g., late-stage chronic liver disease, immune thrombocytopenia purpura).
  • The subject is currently receiving, or is scheduled to receive during the course of the study, an immunomodulating drug other than anti-retroviral chemotherapy (e.g., alpha-interferon, corticosteroid agents at a dose equivalent to hydrocortisone greater than 10 mg/day).
  • The subject has a known hypersensitivity to mouse or hamster proteins.
  • The subject has received another investigational drug study within 30 days prior to screening and/or is scheduled to receive additional investigational drug during the course of the trial in the context of another investigational study.
  • The subject is identified by the investigator as being unable or unwilling to cooperate with study procedures.

Источник: ClinicalTrials.gov, NCT00357656 · запись обновлена в реестре 19 мая 2021.

Дизайн и результаты

ДизайнРандомизированное, открытое (без ослепления), параллельные группы; цель — лечение
Включено участников (факт, все страны)85
Что измеряют — первичные конечные точки (1), вторичных — 6
  • Cumulative Packed Red Blood Cell (PRBC) Volume in the Drainage Fluid During the First 24 Hours Following Surgery in Subjects Receiving ADVATE (rAHF-PFM) by Bolus (BI) or Continuous Infusion (CI) — During the first postoperative 24 hours every 8 hours ± 30 minutes the drainage fluid was to be recorded..

Цель исследования

The purpose of this study is to compare the hemostatic efficacy and safety of continuous infusion versus intermittent bolus infusion in the peri- and post-operative setting, employing rAHF-PFM, a recombinant antihemophilic factor manufactured without added human or animal proteins, in previously treated patients with severe or moderately severe hemophilia A (baseline factor VIII level \<= 2% of normal) who are undergoing unilateral major orthopedic surgery that requires drain placement. The total study period per subject (from consent to study completion) will vary from approximately 9 to 26 weeks and will involve clinical and laboratory assessments.

Где проходит

3 центра в 3 городах

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00357656 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.